ରୋଲାପିଟାଣ୍ଟ

ରୋଲାପିଟାଣ୍ଟ
Clinical data
Pronunciation	/roʊˈlæpɪtænt/ roh-LAP-i-tant
Trade names	Varubi (US), Varuby (EU)
Synonyms	SCH 619734
AHFS/Drugs.com	monograph
MedlinePlus	a615041
data	EU EMA: yes; US DailyMed: Rolapitant;
Pregnancy; category	US: N (Not classified yet) ; ;
Routes of; administration	By mouth (tablets), intravenous
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	nearly 100%
Protein binding	99.8%
Metabolism	CYP3A4
Metabolites	C4-pyrrolidine-hydroxylated rolapitant (major)
Elimination half-life	169–183 hours
Excretion	Feces (52–89%), urine (9–20%)
Identifiers
	IUPAC name (5S,8S)-8-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)- 8-phenyl-1,7-diazaspiro[4.5]decan-2-one;
ECHA InfoCard	100.243.022
Chemical and physical data
Formula	C25H26F6N2O2
Molar mass	୫୦୦.୪୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c(c4)cc(C(F)(F)F)cc4C(C)OCC3(c2ccccc2)NCC1(CC3)NC(=O)CC1;
	InChI InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1; Key:FIVSJYGQAIEMOC-ZGNKEGEESA-N;

ରୋଲାପିଟାଣ୍ଟ, (ଇଂରାଜୀ ଭାଷାରେ Rolapitant), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଭାରୁବି ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା କେମୋଥେରାପି ଜନିତ ଅଇ ଓ ବାନ୍ତିର (CINV) ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୨] ଏହା ସାଧାରଣତଃ କେମୋଥେରାପି ଦେବାର ୨୪ ଘଣ୍ଟାରୁ ଅଧିକ ସମୟ ପରେ ହେଉଥିବା ଅଇ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ କିମ୍ବା ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ବ୍ୟବହୃତ ହୁଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ହିକ୍କା, ମୁଣ୍ଡ ବୁଲାଇବା, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ଥକ୍କାପଣ ହୋଇପାରେ ।^[୨] ^[୩] ଏହା ସେଣ୍ଟ ଜନ ୱର୍ଟ ସହିତ ପ୍ରତିକ୍ରିୟା କରିଥାଏ ।^[୩] ଏହା ଏନ‌କେ<sub id="mwHw">୧</sub> ( NK <sub id="mwHw">1</sub> )ରିସେପ୍ଟରକୁ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ । ^[୩]

୨୦୧୫ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ରୋଲାପିଟାଣ୍ଟ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୪] ୨୦୧୭ରେ ୟୁରୋପରେ ଏହାକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା କିନ୍ତୁ ପରେ ସେହି ଅନୁମୋଦନ ପ୍ରତ୍ୟାହାର କରାଯାଇଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ଏକ ମାତ୍ରାର ମୂଲ୍ୟ ପ୍ରାୟ ୬୭୦ ଡଲାର ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Varubi- rolapitant tablet". DailyMed. 6 August 2019. Archived from the original on 26 October 2020. Retrieved 21 August 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Rolapitant Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 18 October 2021.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Varuby" (PDF). Archived (PDF) from the original on 8 May 2020. Retrieved 18 October 2021.
↑ "DailyMed - VARUBI- rolapitant tablet". dailymed.nlm.nih.gov. Archived from the original on 26 October 2020. Retrieved 18 October 2021.
↑ "Varuby". Archived from the original on 26 June 2021. Retrieved 18 October 2021.
↑ "Varubi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 18 October 2021.

[Varubi_FDA_label-1] ୧.୦ ^୧.୧ "Varubi- rolapitant tablet". DailyMed. 6 August 2019. Archived from the original on 26 October 2020. Retrieved 21 August 2020.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ "Rolapitant Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 18 October 2021.

[EPAR2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Varuby" (PDF). Archived (PDF) from the original on 8 May 2020. Retrieved 18 October 2021.

[4] "DailyMed - VARUBI- rolapitant tablet". dailymed.nlm.nih.gov. Archived from the original on 26 October 2020. Retrieved 18 October 2021.

[5] "Varuby". Archived from the original on 26 June 2021. Retrieved 18 October 2021.

[Price2021-6] "Varubi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 18 October 2021.

[୨]

[୩]

[୧]

[୪]

[୫]

[୬]

Clinical data

Pronunciation	/roʊˈlæpɪtænt/ roh-LAP-i-tant
Trade names	Varubi (US), Varuby (EU)
Synonyms	SCH 619734
AHFS/Drugs.com	monograph
MedlinePlus	a615041
data	EU EMA: yes US DailyMed: Rolapitant
Pregnancy category	US: N (Not classified yet)
Routes of administration	By mouth (tablets), intravenous
Legal status
Legal status	US: ℞-only ^[୧] EU: Rx-only
Pharmacokinetic data
Bioavailability	nearly 100%
Protein binding	99.8%
Metabolism	CYP3A4
Metabolites	C4-pyrrolidine-hydroxylated rolapitant (major)
Elimination half-life	169–183 hours
Excretion	Feces (52–89%), urine (9–20%)^[୧]
Identifiers
IUPAC name (5S,8S)-8-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)- 8-phenyl-1,7-diazaspiro[4.5]decan-2-one
ECHA InfoCard	100.243.022
Chemical and physical data
Formula	C₂₅H₂₆F₆N₂O₂
Molar mass	୫୦୦.୪୯ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c(c4)cc(C(F)(F)F)cc4C(C)OCC3(c2ccccc2)NCC1(CC3)NC(=O)CC1
InChI InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1 Key:FIVSJYGQAIEMOC-ZGNKEGEESA-N